Financial Performance - The company's revenue for Q3 2023 reached ¥255,856,692.92, representing a year-on-year increase of 21.42%[5] - Net profit attributable to shareholders for the same period was ¥52,373,890.33, up 51.10% compared to the previous year[5] - The basic earnings per share for Q3 2023 was ¥0.39, reflecting a 14.71% increase year-on-year[6] - Operating income for the year-to-date period reached ¥759,108,812.47, marking a 32.50% increase compared to the same period last year[5] - Total operating revenue for the first three quarters of 2023 reached ¥759,108,812.47, a 32.5% increase from ¥572,923,877.69 in the same period of 2022[23] - Net profit for the first three quarters of 2023 was ¥130,079,517.77, representing a 41% increase compared to ¥92,244,874.86 in the same period of 2022[24] - Earnings per share for the first three quarters of 2023 was ¥1.06, compared to ¥0.94 in the same period of 2022[25] Assets and Liabilities - Total assets as of the end of the reporting period amounted to ¥2,833,456,062.46, a 35.21% increase from the end of the previous year[6] - The company's total assets amounted to ¥2,833,456,062.46, up from ¥2,095,542,810.84, reflecting a growth of around 35%[20] - Total current assets reached ¥2,436,375,959.60, compared to ¥1,762,493,763.41 at the end of 2022, marking an increase of approximately 38%[18] - The total liabilities increased to ¥1,578,160,045.49 from ¥1,467,956,158.94, showing a rise of approximately 7.5%[20] - The company's total liabilities increased to ¥1,641,208,849.14 in Q3 2023, up from ¥1,519,332,985.64 in Q3 2022[24] Cash Flow - The company reported a significant increase in cash flow from financing activities, with a net outflow of ¥2,158.76 million due to new share issuance[12] - The company reported a net cash flow from operating activities of -¥37,659,334.94, indicating a 136.00% decline year-on-year[12] - In the first three quarters of 2023, the net cash flow from operating activities was -37,659,334.94, a significant decrease compared to 104,607,392.76 in the same period of 2022[27] - Total cash inflow from operating activities was 634,898,516.25, down from 665,840,114.75 in the previous year, reflecting a decline of approximately 4%[27] - Cash outflow from operating activities increased to 672,557,851.19, compared to 561,232,721.99 in 2022, marking an increase of about 20%[27] - The net cash flow from investing activities was -90,465,388.28, worsening from -15,630,534.24 in the same period last year[28] - Cash inflow from financing activities rose significantly to 546,246,866.04, compared to 43,756,692.20 in 2022, indicating a substantial increase[28] - The net cash flow from financing activities was 467,465,947.82, a turnaround from -22,706,189.78 in the previous year[28] Assets Composition - The company's non-current assets totaled ¥397,080,102.86, up from ¥333,049,047.43, indicating an increase of about 19%[20] - Accounts receivable rose significantly to ¥285,343,593.74, up from ¥134,708,996.53, indicating an increase of about 111%[18] - Inventory levels increased to ¥1,151,531,427.25 from ¥982,857,113.00, which is an increase of about 17%[18] - The company reported a significant increase in prepayments to ¥87,385,463.20 from ¥73,633,063.86, which is an increase of approximately 18.6%[18] Shareholder and Market Activity - The company has not disclosed any new product developments or market expansion strategies in the current report[16] - There are no significant changes in the shareholder structure or any new mergers and acquisitions reported during this period[16] Research and Development - Research and development expenses for the first three quarters of 2023 amounted to ¥32,244,707.94, an increase from ¥25,330,132.86 in the same period of 2022[24] Tax and Financial Income - The company reported a financial income of ¥9,365,217.04 in the first three quarters of 2023, compared to ¥1,828,352.30 in the same period of 2022[24] - The company reported a significant increase in tax refunds received, totaling 14,794,768.82 compared to 3,722,422.89 in the previous year[27]

浙江亚光科技股份有限公司独立董事 浙江亚光科技股份有限公司（以下简称"公司"）第三届董事会第十一次会议 于 2023 年 10 月 27 日召开，根据《公司章程》、《上市公司独立董事规则》 和《上市公司治理准则》等相关规定，我们作为公司独立董事，对会议资料进行 了认真审阅，基于自身的独立判断，现就公司第三届董事会第十一次会议审议的 相关事项发表如下独立意见： 一、关于《公司 2023 年第三季度报告》的独立意见 经核查，我们认为：公司 2023 年第三季度报告全面、准确地反映了公司报 告期内的财务状况和经营成果，不存在虚假记载、误导性陈述和重大遗漏。对报 告编制过程核查亦没有发现编制和审核人员存在泄露内幕信息的行为。 综上所述，我们同意该议案。 （以下无正文） 独立董事：潘维力、沈习武、杨东升 2023 年 10 月 27 日 [ 本页无正文，为浙江亚光科技股份有限公司独立董事关于公司第三届董事会第 十一次会议相关议案的独立意见签字页 ] 独立董事签字： 潘维力： 沈习武： 关于公司第三届董事会第十一次会议相关议案的独立意见 杨东升： 2023 年 10 月 27 日 ...

证券代码：603282 证券简称：亚光股份 公告编号：2023-035 浙江亚光科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江亚光科技股份有限公司（以下简称"公司"）于 2023 年 10 月 13 日上 午 11:00-12:00 在上证路演中心以网络互动形式召开"2023 年半年度业绩说明 会"，现将有关事项公告如下： 二、投资者提出的主要问题及公司的回答情况 公司对投资者在本次业绩说明会上提出的普遍关心的问题给予了回复，现将 主要问题及回复整理如下： 问题 1：公司在半年报的基础上，可否对毛利率的变动趋势做个预期，毕竟 很多产品是定制化，如何维持毛利率稳中有升，通过品牌的效应，保证公司的 毛利率？ 回复：感谢您的关注。公司产品毛利率受多种因素影响，其中，不锈钢的价 格波动影响较大，随着不锈钢价格的趋稳，公司的毛利率也会稳中略增，公司 MVR 产品毛利率相对于制药机械毛利率低的多，随着 MVR 产品销售占比的提升， 公司的综合毛利率可能会出现阶段性波动， ...

关于全资子公司增加注册资本的进展公告 证券代码：603282 证券简称：亚光股份 公告编号：2023-034 浙江亚光科技股份有限公司 类型：有限责任公司（自然人投资或控股的法人独资）； 法定代表人：陈静波； 注册资本：捌仟万元整； 公司住所：大厂县潮白河工业区； 成立日期：2013 年 05 月 28 日； 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江亚光科技股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日召开 第三届董事会第十次会议，审议通过了《关于增加全资子公司注册资本的议案》， 公司拟向全资子公司河北乐恒节能设备有限公司（以下简称"乐恒节能"）以现 金方式增加注册资本 1,000 万元人民币。增资后乐恒节能的注册资本为 8,000 万元人民币，公司持股比例 100%。具体内容详见公司于 2023 年 8 月 26 日在上 海证券交易所网站（www.sse.com.cn）披露的相关公告（公告编号：2023-028）。 根据《上海证券交易所股票上市规则》、《公司章程》等有关规定，公司本 次对外投资 ...

证券代码：603282 证券简称：亚光股份 公告编号：2023-033 浙江亚光科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023年10月13日(星期五) 上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 09 月 28 日(星期四) 至 10 月 12 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 agt@china-yaguang.com 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 浙江亚光科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 26 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入 地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 10 月 13 ...

证券代码：603282 证券简称：亚光股份 公告编号：2023-032 本次利润分配方案经公司 2023 年 9 月 11 日的 2023 年第二次临时股东大会审 议通过。 浙江亚光科技股份有限公司 2023 年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.30 元（含税） 相关日期 | 股份类别 | | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | A | 股 | 2023/9/26 | － | 2023/9/27 | 2023/9/27 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 二、 分配方案 1. 发放年度：2023 年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配 ...

中国上海市南京西路 1515 号静安嘉里中心一座 10 层 200040 10/F, Tower 1, Jing An Kerry Centre, 1515 West Nanjing Road, Shanghai 200040, China 电话 Tel: +86 21 6019 2600 传真 Fax: +86 21 6019 2697 电邮 Email: shanghai@tongshang.com 网址 Web: www.tongshang.com 关于浙江亚光科技股份有限公司 2023 年第二次临时股东大会的法律意见书 致：浙江亚光科技股份有限公司 一. 关于本次股东大会的召集、召开程序 北京市通商律师事务所上海分所(以下简称"本所")接受浙江亚光科技股份有 限公司(以下简称"公司")的委托，指派本所律师(以下简称"本所律师")根据《中华 人民共和国证券法》《中华人民共和国公司法》《上市公司股东大会规则》等法律、 法规、规范性文件(以下统称"法律法规")及《浙江亚光科技股份有限公司章程》 (以下简称"公司章程")的规定就公司 2023 年第二次临时股东大会(以下简称"本 次股东大会")相关事宜出具法律 ...

证券代码：603282 证券简称：亚光股份 公告编号：2023-031 浙江亚光科技股份有限公司 2023 年第二次临时股东大会决议公告 | 1、出席会议的股东和代理人人数 | 13 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 72,765,388 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 54.3755 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，董事长陈国华主持，会议以现场投票结合网络 投票的方式进行表决，会议的召集、召开和表决方式符合《公司法》、《上市公 (一) 股东大会召开的时间：2023 年 9 月 11 日 (二) 股东大会召开的地点：浙江温州经济技术开发区滨海园区滨海八路 558 号公司行政楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 司股东大会规则》及《公司章程》的规定。 (五) 公司董事、监事和董事会秘书的出席情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并 ...

股票代码：603282 公司简称：亚光股份 浙江亚光科技股份有限公司 2023 年第二次临时股东大会 会议资料 会议召开时间：2023 年 9 月 11 日 目 录 | 2023 | 年第二次临时股东大会参会须知 | | 1 | | --- | --- | --- | --- | | 2023 | 年第二次临时股东大会会议议程 | | 2 | | 议案 | 1：公司 2023 年半年度利润分配方案 | | 4 | 浙江亚光科技股份有限公司 2023 年第二次临时股东大会 2023 年第二次临时股东大会参会须知 尊敬的各位股东： 为维护投资者的合法权益，确保浙江亚光科技股份有限公司（以下简称"公 司"）2023 年第二次临时股东大会的顺利召开，依据中国证券监督管理委员会 《上市公司股东大会规则》等有关规定，制定会议须知如下： 一、为保证股东大会的顺利召开，切实维护公司股东的合法权益，除出席会 议的股东，公司董事、监事、高级管理人员，公司聘请的律师及董事会邀请的人 员外，公司有权依法拒绝其他人员进入会场。 二、为保证股东大会的顺利召开，切实维护公司股东的合法权益，除出席会 议的股东，公司董事、监事、高级管理人员， ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥503,252,119.55, representing a 38.94% increase compared to ¥362,200,288.12 in the same period last year[20] - The net profit attributable to shareholders of the listed company was ¥77,993,383.56, up 30.20% from ¥59,902,902.15 in the previous year[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥80,970,941.37, reflecting a 38.94% increase from ¥58,279,610.34 year-on-year[20] - The company's basic earnings per share increased by 11.67% to CNY 0.67 compared to the same period last year[21] - Net profit grew by 30.20% year-on-year, driven by the rapid development of the new energy industry and increased sales scale of MVR[21] - Operating revenue rose by 38.94% compared to the previous year, attributed to the commissioning of new production capacity from the chemical and pharmaceutical equipment project[21] Cash Flow and Assets - The net cash flow from operating activities was -¥76,915,130.86, a significant decline of 345.18% compared to ¥31,370,453.90 in the same period last year[20] - The net cash flow from operating activities decreased by 345.18% year-on-year, mainly due to increased cash payments for new orders[21] - The company's cash and cash equivalents increased to ¥607.66 million, representing 22.60% of total assets, up 173.62% from ¥222.08 million last year[70] - Accounts receivable rose to ¥233.31 million, accounting for 8.68% of total assets, a 73.19% increase from ¥134.71 million year-over-year[70] - Inventory decreased to ¥1.14 billion, making up 42.36% of total assets, down 15.89% from ¥982.86 million last year[70] - Contract liabilities increased to ¥1.04 billion, representing 38.78% of total assets, up 6.84% from ¥975.94 million year-over-year[70] Shareholder and Dividend Information - The company plans to distribute a cash dividend of ¥3 per 10 shares (including tax) based on the total share capital as of the dividend distribution date[5] - The company reported a commitment to not transfer or delegate management of shares held prior to the IPO for a lock-up period of 36 months[101] - The lock-up period will automatically extend by 6 months if the stock price falls below the issue price for 20 consecutive trading days within the first 6 months post-IPO[101] - The company has committed to not reduce shareholdings during the lock-up period and will comply with relevant laws and regulations regarding share reduction post-lock-up[102] Market and Industry Insights - The pharmaceutical equipment manufacturing industry is projected to grow at a compound annual growth rate (CAGR) of approximately 20% from 2016 to 2020, with the market size expected to exceed 130 billion yuan by 2020[43] - The global pharmaceutical industry is experiencing growth driven by factors such as population growth, aging society, and increasing health awareness, which directly impacts the demand for pharmaceutical equipment[42] - The global MVR steam machinery market size grew from $12.95 billion in 2014 to $16.88 billion in 2019, achieving a compound annual growth rate (CAGR) of 5.44%[46] - The domestic MVR industry experienced explosive growth from 2013 to 2018, driven by increasing industrial development and higher efficiency demands[47] Technological Development and Innovation - The company has developed a range of steam compressors and MVR systems, enhancing its technological competitiveness in the market[30] - The company holds 207 authorized patents and 18 software copyrights, showcasing its commitment to innovation and technology development[55] - The company has multiple ongoing R&D projects and has developed core technologies in pharmaceutical equipment and steam compression systems, but risks exist regarding potential leaks of these core technologies[84] - The company emphasizes the importance of continuous innovation and technology development to maintain competitiveness and avoid risks of declining gross margins[87] Environmental and Sustainability Efforts - The company has committed to green low-carbon development, focusing on renewable energy and environmental protection industries[98] - The company’s wastewater treatment facilities have a processing capacity of 2 m³/h, and they operate normally, ensuring compliance with discharge standards[96] - The company has implemented measures to reduce noise levels by 10-15 dB through equipment layout optimization and sound insulation techniques[97] - The company has not faced any administrative penalties related to environmental issues during the reporting period[94] Risks and Challenges - The company faces risks related to the economic cycle of the pharmaceutical and energy-saving equipment industries, which significantly affect product market growth depending on the economic conditions of downstream industries[82] - The company is exposed to price volatility of key raw materials such as steel and titanium, which can impact cost management and overall profitability[85] - The company is at risk of talent loss due to intensified competition for skilled R&D personnel, which could weaken its technological advantages[88] Corporate Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[6] - There are no violations of decision-making procedures regarding external guarantees[6] - The company confirmed compliance with all regulatory requirements, with no violations reported regarding guarantees[109] - The company has maintained a good integrity status, with no records of unfulfilled court judgments or significant overdue debts[110]